AR-targeting PROTACs, notably ARCC-4 (an enzalutamide-basedvon Hippel–Lindau (VHL)-recruiting AR PROTAC), have been proposedand shown to be superior to enzalutamide.195 The primary advantages include inducing apoptosis and inhibitingthe proliferation of AR-amplified prostate cancer cells, as well aseffectively degrading clinically relevant AR mutants associated withantiandrogen therapy. Here, VHL is linked to prostate cancer.